The RON receptor tyrosine kinase is a member of the MET proto-oncogene family that has been implicated in regulating motile-invasive phenotypes in certain types of epithelial cancers. The purpose of this study was to determine if RON expression is altered in primary human colorectal adenocarcinomas. Results from immunohistochemical staining showed that RON is highly expressed in the majority of colorectal adenocarcinomas (29/49 cases). Accumulated RON is also constitutively active with autophosphorylation in tyrosine residues. Moreover, three splicing variants of RON, namely ROND165, ROND160, and ROND155 were detected and cloned from two primary colon cancer samples. These RON variants were generated by deletions in different regions in extracellular domains of the RON b chain. Functional studies showed that expression of ROND160 or ROND155 in MartinDarby canine kidney cells resulted in increased cell dissociation (scatter-like activity). RON variants, ROND160 and ROND155, also exerted the ability to induce multiple focus formation and sustain anchorageindependent growth of transfected NIH3T3 cells. Moreover, NIH3T3 cells expressing ROND160 or ROND155 formed tumors in athymic nude mice and colonized in the lungs. These data suggest that RON expression is altered in certain primary colon cancers. Abnormal accumulation of RON variants may play a role in the progression of certain colorectal cancers in vivo.
Introduction
Colorectal cancer is the second leading cause of cancerrelated deaths in the United States with an estimated 160 000 new cases every year (Greenlee et al., 2000) . Histologically, adenocarcinomas constitute the vast majority (98%) of colorectal tumors (Crawford, 1994) . Inactivation of tumor-suppressor genes including adenomatous polyposis coli (APC) and p53, and activation of oncogenes such as Ras have been linked to the initiation and progression of tumors (Kinzler and Vogelstein, 1998) . However, the ability of tumors to invade and metastasize requires further cellular disorganization and genetic changes (Portera et al., 1988; Yokota, 1999) . Clinically, it is metastasis that marks a tumor as malignant because benign neoplasms do not metastasize (Portera et al., 1988; Crawford, 1994; Yokota, 1999) . Thus, understanding the mechanisms by which colorectal cancer metastasizes is of great physiological and clinical importance.
Metastasis is a complicated process involving cell migration, adhesion, invasion, tissue destruction, and localization in remote sites (Portera et al., 1988; Yokota, 1999) . Invasiveness allows cancer cells to penetrate into blood vessels, lymphatics, and body cavities, which provides the opportunity to spread (Portera et al., 1988; Crawford, 1994; Yokota, 1999) . Many factors have been implicated in the invasiveness of epithelial cancers (Dorudi and Hart, 1993) . Recently, members of the MET proto-oncogene family have drawn special attention (Birchmeier et al., 1997; Vande Woude et al., 1997) . The MET family, including MET and RON, belongs to a distinct subfamily of receptor tyrosine kinases (Rubin et al., 1993; Porter and Vaillancourt, 1998) . They have the ability to induce cell dissociation, migration, and matrix invasion (Comoglio et al., 1999) . These features, collectively known as invasive growth, are controlled by a genetic program that is evolutionally conserved in the MET family members (Birchmeier et al., 1997; Vande Woude et al., 1997; Comoglio et al., 1999) .
The RON cDNA was originally cloned from human foreskin keratinocytes (Ronsin et al., 1993) . Mature RON is a 180 kDa heterodimeric protein composed of a 40 kDa extracellular a chain and a 150 kDa transmembrane b chain with intrinsic protein tyrosine kinase activity (Ronsin et al., 1993) . RON is activated by macrophage-stimulating protein (MSP) (Skeel et al., 1991; Gaudino et al., 1994; Wang et al., 1994a) , also known as hepatocyte growth factor-like protein (Han et al., 1991) . MSP is a serum protein that is constitutively expressed by liver cells as an inactive form and requires proteolytic conversion for receptor binding (Skeel et al., 1991; Wang et al., 1994b) . Recent studies have shown that RON is highly expressed in the majority of primary breast carcinomas, but not in normal breast epithelia or benign lesions (Maggiora et al., 1998) . RON is also overexpressed in established human colorectal carcinoma cell lines including HT29 , from which a novel RON variant was cloned . These results suggest that RON expression is deregulated in breast and colorectal cancer cells. Alteration of RON expression in colon cancer cells could result in the acquisition of a phenotype characterized by the ability of cells to migrate and penetrate through an artificial membrane Wang et al., 2000) , which correlates with the metastatic phenotype displayed in vivo by malignant tumors. Thus, it is hypothesized that abnormal accumulation and activation of RON are required in vivo for the acquisition of motile-invasive phenotypes during the progression of certain colorectal adenocarcinomas, particularly at metastatic stages.
The present work was to determine if RON expression is altered in primary human colorectal adenocarcinomas. Immunohistochemical analysis was used to detect RON expression in 49 adenocarcinoma samples along with nine normal colorectal mucosa specimens. Experiments were also performed to study if RON variants are generated in primary tumors. Our results indicate that RON is highly expressed in the majority of colorectal adenocarcinomas. Overexpression also results in the generation of different and active RON variants that were identified and cloned from tumor samples.
Functional analysis indicates that altered RON expression might play an important role in pathogenesis of colorectal tumors.
Results

Expression of RON in normal colorectal mucosa and primary colorectal adenocarcinomas
A total of 58 colorectal tissue specimens were examined for RON expression by immunohistochemical staining. Of these, 49 samples were of colon adenocarcinomas and nine were of normal colorectal mucosa obtained from nontumor-related surgery. The RON expression was first determined in normal colorectal mucosa. RON was expressed in normal colorectal epithelia in all nine normal samples with similar intensities and patterns of staining. Representative results are shown in Figure 1 . By using a semiquantitative scoring method (Allred et al., 1998) , these nine samples scored 3, 3, 3, 3, 4, 4, 4, 5, and 5, respectively. The mean score was 3.8. The control serum (from preimmunized rabbit) did not provide any meaningful staining. The patterns of the RON staining are unique. RON is accumulated in the cytoplasm and cell surface as condensed granules. In cells close to the luminal surface, RON is universally expressed in lining epithelia including goblet cells (Figure 1a ). Immunoreactive RON was also detected in cells at the bottom of the crypt with similar expression patterns. However, the intensity of the staining is relatively weak (Figure 1b ). These characteristics of the staining were confirmed by using three individual anti-RON antibodies that recognize different regions in the RON protein (data not shown). Immunoreactive RON was detected in all 49 tumor samples. Among these, 20 samples had RON expression at levels similar to those found in normal colorectal epithelia. The scores of these 20 samples were 3 (seven cases), 4 (eight cases), and 5 (five cases) with a mean score of 3.90. Increased RON expression was found in 29 cases (59.2%) with scores of 6 (seven cases), 7 (11 cases), and 8 (11 cases). The mean score of these 29 cases was 7.14, which is significantly higher than that from normal colon tissues. Representative results are shown in Figure 2 . Almost all cancerous cells were stained with anti-RON antibody. High levels of RON accumulation were found in samples characterized as highly or poorly differentiated adenocarcinomas (Figure 2a, b) . Unlike its expression in normal colorectal mucosa, the RON protein was distributed in the cytoplasm of cancerous cells as a diffuse pattern. However, the granular staining pattern was often seen in tumors that express relatively normal levels of RON (Figure 2c) . A detailed analysis for correlation between the levels of RON expression and the degree of tumor differentiation was conducted, but the statistical significance was not established. The correlation between the intensity of RON staining and clinicopathological parameters, including depth of invasion and vascular involvement, was not observed.
Constitutive activation of RON in primary colorectal adenocarcinomas
To determine if accumulated RON is constitutively active in vivo, cellular proteins from four frozen tumor samples were tested in the phosphotyrosine assay. These samples were from matched tumors with immunohistochemical scores of 7-8. Two normal colon samples from nontumor operation were used as controls. RON was immunoprecipitated with mAb ID2 and detected in Western blotting with mAb 4G10 to phosphotyrosine. Results are shown in Figure 3 . Phosphorylated RON was detected in all four tumor samples (Figure 3a , lanes 3-6), although the levels of RON vary among these four samples (Figure 3b ). No phosphorylated RON was detected in control specimens (Figure 3a, lanes 1 and 2) . These results indicate that the increased RON expression in certain colorectal cancers is accompanied by constitutive phosphorylation in vivo. 
Identification of RON variants expressed in primary colorectal carcinomas
Our previous studies have found a novel RON variant in certain colon cancer cell lines such as HT29 . To determine if RON variants are generated in primary colorectal adenocarcinomas, tissue lysates prepared from 11 frozen tumor samples were analysed by Western blotting. The results are shown in Figure 4 . RON was expressed in all 11 tumor samples, mostly displayed as a 180 kDa single-chain pro-RON and a 145 kDa RON b chain (derived from mature RON). However, in tumor samples CT34 and CT42, three proteins with molecular mass at p165, p155, and p140 were detected by anti-RON antibody. Similar results were also obtained by using another anti-RON antibody that recognizes different regions of the RON protein (data not shown). Owing to limited amounts of available samples, the phosphorylation assay was not performed. In contrast, RON variants were not detected in samples prepared from 5-colorectal normal mucosa (data not shown). Thus, the presence of these three different-sized proteins suggests that RON variants are produced in colorectal tumor samples CT34 and CT42.
Molecular cloning of RON variants from primary colorectal carcinomas
To clone RON variants expressed in samples CT34 and CT42, reversed transcription-polymerase chain reaction (RT-PCR) was performed using total RNA isolated from these two tumor samples. RNA from normal colorectal mucosa was used as controls. A pair of oligoprimers that cover the most extracellular regions (from 1311 to 2919) of the RON b chain was designed. This region has been previously found containing deletions in exons 5, 6, and 11 Collesi et al., 1996) . Results from the RT-PCR analysis are shown in Figure 5 . A single 1.6 kb PCR fragment (designated as CtR-1) was amplified from tumor samples CT01, 02, 07, 11, 15, 35, 36, 41, and 43 . This fragment was also found in CT34 and CT42. Interestingly, three additional cDNA fragments (designated as CtR-2, 1.5 kb; CtR-3, 1.3 kb; and CtR-4, 1.1 kb, respectively) were also amplified from CT34 or CT42 RNA sample.
Results from DNA sequence analysis of the amplified PCR fragments are shown in Figure 6 . The sequences of CtR-1 fragment are identical to those found in the wildtype (wt) RON b chain and contain no mutation or deletion. CtR-2, -3, and -4 also encode the part of the RON b chain, but contain different in-frame deletions. CtR-2 had a deletion of 147 nucleotides, which encodes 49 amino acids; CtR-3 had a deletion of 327 nucleotides, which encodes 109 amino acids; and CtR-4 had a combined deletion of 147 and 327 nucleotides. By comparison with genomic sequence of the RON gene with the cloned fragment, it is clear that the deletion of 49 amino acids occurs at exon 11. The deletion of 109 amino acids occurs at exons 5 and 6. The deletion of 49 and 109 amino acids is the result of the combination of exons 5, 6, and 11. This is a novel RON variant (designated as ROND155, based on the calculated molecular weight) that has not been discovered previously. These data demonstrated that the splicing of the RON mRNA at different regions occur in these two primary colorectal cancer samples, which results in the expression of different RON variants ( Figure 4 ).
Different expression patterns of RON variants in MDCK cells
To study biological activities of three RON variants in more detail, the cDNA encoding ROND165, ROND160, or ROND155 were constructed by replacing the corresponding fragment in the wtRON cDNA with the cloned CtR-2 or CrR-4 fragment, respectively. Structural differences among these three RON variants are illustrated in Figure 7 .
Expression of the three RON variants was achieved by transfection of Martin-Darby canine kidney (MDCK) cells with pcDNA3.1 expression vector. Results are shown in Figure 8 . In cells expressing wtRON, a 180 kDa single-chain pro-RON and a 145 kDa RON b chain were observed, indicating that pro-RON is converted into the two-chain form. However, a single 165 kDa protein was seen in cells Amplification of RON-variant cDNA fragments from primary colorectal carcinoma samples. RT-PCR was performed using a pair of oligoprimers covering nucleotides 1311-2919. Four prominent bands, designated as CtR-1, -2, -3, and -4, with sizes of 1.6, 1.5, 1.3, and 1.1 kb, respectively, were amplified. A full length of RON cDNA was used as a positive control (data not shown). All four fragments were isolated for DNA sequence analysis expressing ROND165, indicating that the protein is an uncleaved pro-ROND165 protein . In cells expressing ROND160, two proteins were detected, one is the single-chain pro-ROND160 and the other is the ROND160 b chain, suggesting that pro-ROND160 is proteolytically processed. In cells expressing ROND155, only a single protein with a molecular mass of 140 kDa was detected. The size of this protein is slightly smaller than the expected pro-ROND155. These results indicate that the proteolytic conversion occurs in RON variant ROND160, but not in ROND165 and ROND155.
The tyrosine phosphorylation assay was also performed confirming that ROND165, ROND160, and RONp155 are autophosphorylated at tyroine residues, indicating that the three RON variants are
tgt ggc tgg tgt ggg aac atg tgc ggc cag cag aag gag tgt cct ggc tcc tgg caa cag gac cac tgc 
aac ttc tac ctt cac cct tct ggt ctg gtg cct gag gga acc cat cag gtc act gtg ggc caa agt ccc
cgg cca ctg ccc aag gac agc tca aaa ctc aga cca gtg ccc cgg aaa gac ttt gta gag gag ttt gag ↑E6
gaa ctg gag ccc ttg ggc acc cag gca gtg ggg cct acc aac gtc agc ctc acc gtg act aac atg cca
ggc aag cac ttc cgg gta gac ggc acc tcc gtg ctg aga ggc ttc tct ttc atg gag cca gtg ctg ata ↑E7
V gca gtg caa ccc ctc ttt ggc cca cgg gca gga ggc acc tgt ctc act ctt gaa ggc cag agt ctg tct gta
acc agc cgg gct gtg ctg gtc aat ggg act gag tgt ctg cta gca cgg gtc agt gag ggg cag ctt tta ↑E8
gcc aca ccc cct ggg gcc acg gtg gcc agt gtc ccc ctt agc ctg cag gtg ggg ggt gcc cag gta cct
N ggt tcc tgg acc ttc cag tac aga gaa gac cct gtc gtg cta agc atc agc ccc aac tgt ggc tac atc aac
cac atc acc atc tgt ggc cag cat cta act tca gca tgg cac tta gtg ctg tca ttc cat gac ggg ctt
gca gtg gaa agc agg tgt gag agg cag ctt cca gag cag cag ctg tgc cgc ctt cct gaa tat gtg gtc ↑E10
gac ccc cag gga tgg gtg gca ggg aat ctg agt gcc cga ggg gat gga gct gct ggc ttt aca ctg cct
A ggc ttt cgc ttc cta ccc cca ccc cat cca ccc agt gcc aac cta gtt cca ctg aag cct gag gag cat gcc
aag ttt gag tat att ggg ctg ggc gct gtg gct gac tgt gtg ggt atc aac gtg acc gtg ggt ggt gag ↑E11
tgc cag cac gag ttc cgg ggg gac atg gtt gtc tgc ccc ctg ccc cca tcc ctg cag ctt ggc cag gat
gcc cca ttg cag gtc tgc gta gat ggt gaa tgt cat atc ctg ggt aga gtg gtg cgg cca ggg cca gat ↑E12
A ggg gtc cca cag agc acg ctc ctt ggt atc ctg ctg cct ttg ctg ctg ctt gtg gct gca ctg gcg act gca 
Scatter-like activities of MDCK cells expressing different RON variants
To determine if RON variants exert biological functions, scatter-like activity was tested in transfected MDCK cells. Results are shown in Figure 9 . Control MDCK cells grew as clusters. Addition of MSP did not cause any cell scatter-like activity (Figure 9a ). In contrast, MDCK cells expressing wtRON displayed scatter-like activity after MSP stimulation (Figure 9b ). This effect was not seen when MSP was absent (data not shown). Expression of ROND160 or ROND155 resulted in dramatic morphological change and scatter-like activity (Figure 9c, d) . Interestingly, these activities were also seen when MSP was not included in culture (data not shown). Similarly, scatter activity was observed in cells expressing ROND165 in the presence or absence of MSP (data not shown), which is consistent with previously reported data . These results suggest that the three RON variants have the ability to mediate scattering-like activity in a ligandindependent manner.
RON variant-mediated in vitro cell-transforming activities in NIH3T3 cells
Previous studies have shown that the cDNA encoding wtRON or RONDp165 does not have cell-transforming activity when introduced into rodent fibroblasts Santoro et al., 1996) . To determine if cloned RON variants have the ability to transform cells in vitro, the focus-forming assay was performed using NIH3T3 cells as the indicator. The RON mutant (M1254T), which is oncogenic in vivo (Santoro et al., 1998) , was used as the positive control. Results are shown in Figure 10 and Table 1 . Cells transfected with empty vector or wtRON did not produce the visible foci (Figure 10a , b, Table 1 ). In contrast, the M1254T mutant exerted strong focus-forming activity in NIH3T3 cells (Figure 10c and Table 1 ), which is consistent with previously reported results (Santoro et al., 1998) . To our surprise, RONDp160 and ROND155 displayed cell-transforming activity (Figure 10d and data not shown), although their activities were not as strong as the M1254T mutant (Table 1 ). The number and the size of foci in ROND160 or ROND155 expressed cells were less and smaller than those in cells expressing the M1254T mutant. We also tested RON variants in supporting anchorage-independent growth of NIH3T3 cells. Results are shown in Table 1 . Expression of ROND160 or ROND155 results in multiple colony formation when stable transfectants were grown in soft agar; however, the numbers were much less than those produced by RON mutant M1254T. As expected, the colony was not observed in cells expressing wtRON. These results indicate that ROND160 and ROND155 have the ability . Cells expressing individual RON variants were obtained and expanded. Immunoprecipitation was done with 2 mg cellular protein/sample using mAb ID2. RON and the variants were detected by Western blotting with rabbit IgG to the Cterminal peptide of RON. Similar results were also obtained using other cell lines expressing RON variants (data not shown) in vitro to induce and sustain anchorage-independent growth of NIH3T3 cells.
Oncogenic potentials of RON variants in vivo
To determine if 3T3 cells expressing RON variants have abilities to form tumors in vivo, pooled stable transfected cells expressing individual RON variants were inoculated into nude mice and tumor formation was observed. The results are shown in Table 2 and Figure 11 . Inoculation of control 3T3 cells did not produce any tumors in mice. Similarly, cells expressing wtRON did not form any tumors in five mice tested, which is consistent with a previous report (Santoro et al., 1998) . As expected, RON-M1254T cells formed large tumors in all five mice. To our surprise, tumors were found in all five nude mice injected with ROND160 cells. Small tumors were also found in mice inoculated with ROND155 cells. The days of tumor mass onset in these two groups of mice were slightly delayed in comparison with those in RON-M1254T mice. Also, the average size of tumors in RONDp160 and ROND155 mice is smaller than that in RON-M1254T mice. These results demonstrated that the two naturally occurring RON variants have abilities to form tumor in nude mice in vivo.
Metastatic potentials of RON variants in athymic nude mice
To determine if cloned RON variants promote tumor metastasis, a model of experimental metastasis was used to test the ability of RON-variant-expressing cells to colonize and grow in the lungs of athymic nude mice. Results are shown in Table 3 . 3T3 cells transfected with pcDNA3.1 vector alone or expressing wtRON (the negative control) did not form any tumors in the lung within a 12-week period. As expected, multiple tumors were observed in the lungs after injection of RON-M1254T cells into the tail vein of mice (the positive control). However, tumors were observed in the lungs from mice injected with ROND160 or ROND155 cells. The frequencies of tumors in the lungs were relatively low in comparison with those found in mice injected with RON-M1254T cells. Nevertheless, these data suggest that cells expressing ROND160 and ROND155 have the ability to colonize and grow in the lungs of mice in the experimental metastasis model. The focus-forming assay was performed by transfection of NIH3T3 cells (5 Â 10 5 per plate) with 10 mg DNA plasmid, together with 1 mg pSV2-neo. Cells were recultured in low density for 18 days and then scored for the focus formation. The soft-agar assay was conducted using G418 stable lines of NIH3T3 from the above assay. Cells were seeded at a density of 3 Â 10 3 per well. The colonies were counted 3 weeks later. Each value represents the averages (7s.d.) of three independent experiments performed in triplicate
Discussion
The central findings in this report are that RON expression is altered in the certain primary human colorectal adenocarcinomas (29/49 cases, 59.2%). Moreover, we identified three RON variants from two of 11 primary tumor samples. Molecular cloning confirmed that RON variants are derived from abnormal mRNA splicing. All three RON variants, ROND165, ROND160, and RONDp155, have the ability to induce cell scatter in a ligand-independent manner. They also have focusforming activity when introduced into rodent fibroblasts. Results from the in vivo tumor formation assay further confirmed that ROND160 and RONDp155 have abilities to induce tumor formation and colonization in the lung in vivo. To our knowledge, this is the first report showing that two naturally occurring human RON variants possess oncogenic activities. Thus, the current data, together with our previous published results Wang et al., 2000) , suggest that RON expression is deregulated not only in established colon cancer cell lines, but also in primary colorectal adenocarcinomas. The altered RON expression and generation of constitutively active RON variants might participate in the pathogenesis of Differential RON expression has been found previously in normal or malignant colorectal epithelia (Montero-Julian et al., 1998; Okino et al., 1999) . Using colon epithelial cell lines, we have shown that RON is barely detectable in normal or SV-40 transformed colorectal epithelial cells, but highly expressed in a panel of established colon carcinoma cell lines including Colo201 and HT29 . The results from our current studies show that RON is moderately expressed in normal colorectal mucosa with a distinct granular staining pattern. This expression pattern was confirmed using three anti-RON antibodies that recognize different domains in the RON protein. In contrast, high levels of RON expression were found in 29/49 primary colorectal carcinoma samples. The intensity of the staining was quite high in certain cases (Figure 2) . The most striking feature found in immunohistochemical staining is that RON is universally distributed in cancerous cells with diffused cytoplasmic staining. At present, the significance in changing expression patterns between normal and malignant colon tissues is unknown. Nevertheless, these in vivo findings are consistent with our previous in vitro results , suggesting that RON expression is altered in certain primary colorectal adenocarcinomas. Such changes might have a significant implication in the progression of colorectal cancers in vivo.
It needs to point out that our current data differ from a report published previously (Okino et al., 1999) , in which a commercial anti-RON antibody was used in detecting RON expression in colon tissue samples. It was shown that RON is normally expressed in cells at the bottom of the crypt and heterogeneously distributed in cancerous cells without overexpression (Okino et al., 1999) . The discrepancies between these two sets of results are, we believe, the antibody used for the studies. Our experience is that this commercial antibody behaves differently with high reactivity with smooth muscles (our unpublished data). By comparing with our three polyclonal antibodies, this commercial antibody produced different staining patterns. Therefore, whether the results obtained from using this commercial antibody truly reflect RON expression in colorectal tissues require further investigation.
Identification and cloning of three RON variants, ROND165, ROND160, and ROND155, from two colorectal adenocarcinoma samples are important with regard to the pathogenesis of RON in colorectal cancer. ROND165 has been previously found in normal colorectal mucosa and in tumor cells Okino et al., 1999) , suggesting that it may not be involved in tumorigenesis of colorectal epithelia , Okino et al., 1999 . Results from previous studies and our current experiments indicate that this might be the case. ROND160 was first cloned from the established colon tumor cell line HT29 . Now we show that this RON variant is also present in primary colorectal tumors. ROND160 has the ability to induce cell scattering, transformation, and tumor formation in nude mice, suggesting that this altered receptor might play an important role in regulating transforming/motile-invasive phenotypes. RONDp155 is a novel RON variant that has not been reported previously. It induces cell scattering, transformation, and tumor growth in vivo, although its efficiency is relatively low. RT-PCR and Western blot analyses did not find this RON variant in samples derived from five normal colorectal mucosa. It seems that a unique mRNA splicing mechanism(s) is involved in the processing of RON in some colorectal tumors.
Biochemical and biological properties of the cloned three RON variants are different Wang et al. 2000) . Detailed analysis of ROND165 has been reported . ROND165 has an inframe deletion of 49 amino acids in the extracellular domain of the b chain, which was encoded by exon 11. The deletion prevents the proteolytic process of pro-ROND165 and retains the protein in the cytoplasm . In contrast, the deletion of 109 amino acids, which are encoded by exons 5 and 6, did not affect the conversion of pro-ROND160 into the twochain form . The mature ROND160 protein is located on the cell surface and interacts with ligand MSP . ROND155 is the product of a unique spliced RON mRNA that has the combined deletion of exons 5, 6, and 11. ROND155 is present as a single-chain precursor in transfected cells. Currently, it is unknown whether ROND155 is located on the cell surface or inside the cytoplasm. Biochemically, all three RON variants are constitutively active. The autophosphorylation is probably caused by deletions that result in unbalanced cystine residues in the extracellular domain of the RON b chain leading to abnormal dimerization . The three RON variants also Figure 11 RON variants-mediated tumor formation in athymic nude mice. NIH 3T3 cells transfected with empty pMT2 vector, or cDNA encoding wtRON, RONM1254T, RONp155, or RONp160, respectively, were used for inoculation. Five groups of mice, each with 5 animals, were used. Cells (1 Â 10 6 cells) in 0.2 ml PBS were subcutaneously injected into the posterior flank of female nude mice. The mice were checked daily for tumor formation at the site of inoculation. Mice that did not form tumors were observed for up to 8 weeks. Latency was determined as the period of time required for tumor to reach a diameter of 15 mm have the ability to induce spontaneous cell-scattering and migrating activities in a ligand-independent manner Wang et al., 2000, and Figure 9) . Clearly, the generation of the three RON variants, particularly RONp160 and ROND155, provides a molecular mechanism for post-transcriptional activation of RON in primary colorectal adenocarcinomas. Since the abnormal activation of RON led to cell migration, dissociation, and invasion Wang et al., 2000) , it is reasonable to think that RON variants, like ROND160, might play a critical role in regulating motile-invasive phenotypes in certain colorectal carcinomas.
The finding that ROND160 and ROND155 have the ability to cause multiple foci in transfected NIH3T3 cells and to induce tumor formation in athymic nude mice is a surprise. To our knowledge, this is the first naturally occurring human RON variants that have cell-transforming and tumor-growth activities. In contrast, mouse wtRON, also known as STK (Iwama et al., 1994) , has the ability to induce tumor formation in vivo (Peace et al., 2001) . Human wtRON or ROND165 has never showed cell transformation and tumor-formation activities Santoro et al., 1996 Santoro et al., , 1998 Williams et al., 1999) , instead, it induces the motile-invasive phenotypes Santoro et al., 1996) . However, human RON has oncogenic potential. Two reports have showed that the oncogenic forms of RON could be artificially created by point mutations at the RON kinase domain (Santoro et al., 1998; Williams et al., 1999) . The finding that ROND160 and ROND155 have cell-transforming activities is important for the following reasons: (1) Both RON variants were only found in established colon cancer cell line and in certain primary colorectal carcinomas, and not in normal colorectal mucosa (five samples tested). Thus, the generation of ROND160 or ROND155 is a specific event occurring at colorectal tumors, but not at normal mucosa. (2) ROND160 and ROND155 were constitutively active, which led to increased cell scattering (Figure 9 ), migration, and matrix invasion . Thus, they have the ability to transduce signals that activate the motile machinery of the cells, which could play an important role in promoting in vivo the invasive phenotype. (3) The generation of RON variant with transforming activity by the RON gene may have a profound impact on the physiology of colorectal epithelia, and may also represent a unique mechanism for RON in the pathogenesis of certain colorectal carcinomas. Therefore, it will be of great interest in the future to determine if RONDp160 is a critical player in vivo in the pathogenesis of colorectal adenocarcinomas. Targeted expression of RONDp160 or RONDp155 in colorectal tissues using transgenic techniques will be worth trying.
Materials and methods
Colorectal tissue specimens
A total of 49 paraffin-embedded colorectal adenocarcinoma specimens and nine normal colon mucosa samples (39 males and 19 females, aged 23-81 years with a mean age of 60.1) were obtained from the Department of Pathology. Among the 49 fixed tumor samples, 24 cases were well differentiated, 14 cases moderately differentiated, and 11 cases poorly differentiated adenocarcinomas. Normal colon mucosa samples were obtained from noncancer surgical operation. Frozen colorectal samples (11 tumors and five adjacent mucosa) were also obtained and used for isolation of RNA and cellular protein.
Cells and reagents
NIH3T3 cells were from ATCC (Rockville, MD, USA). RE7 is a clone of MDCK cells transfected with the RON cDNA (Wang et al., 1994a) . MSP was provided by Dr EJ Leonard (National Cancer Institute, Frederick, MD, USA). RON mutant cDNA (M1254T) (Santoro et al., 1998) was from Dr G Gaudino (Universita di Torino, Novara, Italy). Mouse mAb to RON (clone ID2) and rabbit IgG antibodies to the extracellular domain or the C-terminal peptide of RON were as described . Mouse mAb 4G10 to phosphotyrosine was from Upstate Biotechnology Inc. (Lake Placid, NY, USA). ECL detection reagents were from Amersham-Pharmacia (Arlington Heights, IL, USA).
RT-PCR and DNA sequencing
Total RNA was isolated from 16 frozen colon tissues using TRIzol (Life Technologies). RT was carried out using 3 mg RNA with a SuperScript Preamplification Kit (Life Technologies). PCR was performed as described using a pair of oligoprimer (5 0 -TGGTCAGTAGCAGCTTCT-CA-3 0 and 5 0 -AGGCAGCAGGATACCAAGGA-3 0 ). The primers were designed to amplify the coding sequences from nucleotides 1311 to 2919 that cover the extracellular regions of the RON b chain (Ronsin et al., 1993; Wang et al., 2000) . PCR fragments were isolated using Qiagen PCR Extraction Kit (QIAGEN Inc., Santa Clarita, CA, USA). Double-stranded DNA sequencing was performed at the University of Colorado Cancer Center DNA Sequence Core Facility.
Construction of RON variant cDNA and transfection in MDCK cells
The cDNA encoding ROND165 or RONDp155 was generated by replacing the corresponding fragment in the wtRON cDNA with the cloned PCR fragment that contains 147 or 147+327 nucleotide deletion. The cDNA encoding ROND160 was used as previously described . Transfection of MDCK cells with pcDNA3.1 (Invitrogen) containing RON variant cDNA was performed as described previously . Cells were selected with 800 mg/ml of G418 and expanded into cell lines. RON variant expression was determined by Western blotting using rabbit anti-RON IgG.
Immunohistochemical staining and data evaluation
Tissue sections (4 mm thick) were dewaxed, rehydrated, and then placed in 10 mm Tris buffer, pH 7.40, containing 150 mm NaCl, 1% BSA, and 0.02 Tween 20. Sections were treated with 0.3% hydroxide in H 2 O for 15 min to block endogenous peroxidase activities and then incubated with preimmunized normal rabbit serum for 60 min. Rabbit anti-RON serum (dilution: 1 : 500) was used as primary antibody. RE7 cells were used as positive controls. The reaction was developed with EnVison+ Sys (DAKO Corp., Carpinteria, CA, USA) and visualized with diaminobenzidine as substrate. The levels of RON expression were assessed using a semiquantitative scoring system (Allred et al., 1998) . This system is the sum of a proportion score and an intensity score. The proportion score is an estimate of the proportion of positive cells on the entire slide and is divided into the following categories: 0, no cells stained; 1, less than 1%; 2, 1-10%; 3, 11-33%; 4, 34-67%; and 5, more than 67%. The intensity score estimates the average staining intensity of positive tumor cells: 0, negative; 1, weak; 2, moderate; and 3, intense. The combined score system ranges from 0 to 8. A combined score of 6 or more was considered positive for RON overexpression.
Immunoprecipitation and Western blotting
Tissue or cell samples were homogenized in lysis buffer as described previously . Equal amounts of cellular proteins were mixed with a monoclonal antibody (mAb) ID2 (1 mg) coupled with protein G-Sepharose beads. Samples were separated in an 8% polyacrylamide gel under reduced conditions and transferred to Immobilon-P membrane (Millipore, Bedford, MA, USA). Western blotting was performed with rabbit IgG to the C-terminal peptide of RON or mAb 4G10, followed by goat anti-rabbit or mouse IgG conjugated with horseradish peroxidase. The reaction was developed with enhanced chemiluminescent reagents and recorded on film.
Assays for cell-scatter-like activity
The assays were performed as described previously (Xiao et al., 2000) . To determine scatter-like activity, cells at 1 Â 10 5 cells/ well were incubated in culture dish overnight and then stimulated with or without 5 nm MSP for 24 h. Cells were stained with crystal violet and photographed.
Cell transformation assays
The focus-forming assay was performed as described (Santoro et al., 1998) with slight modifications. Briefly, NIH3T3 cells (4 Â 10 5 cells/dish) were transfected with 10 mg pMT2 vector containing cDNA encoding wtRON, ROND165, ROND160, or RON-M1254T, respectively. After a 24-h incubation, cells were split at low density into 100 mm-diameter dishes and incubated in DMEM with 5% FBS. One plate was used for focus formation and another for selection of stable tansfectants. Cells were cultured at confluence and screened for focus formation 18 days later. For the anchorage-independent growth assay, stable transfectants were pooled from each transfection. Cells at 2 Â 10 5 in 2 ml DMEM with 5% FBS were seeded in a 35-mm-diameter culture dish containing a 1% agarose underlayer. New medium was added every 4 ays and colonies were scored after 20 days following staining with crystal violet in solution.
In vivo tumorigenesis and metastasis assays These assays were performed as previously described (Santoro et al., 1998; Peace et al., 2001) . Briefly, pooled NIH3T3 cells transfected with pcDNA3.1 vector alone or with cDNA encoding wtRON, RON-M1254T, ROND160, and ROND155, respectively, were harvested from culture dishes and suspended in 0.2 ml serum-free DMEM prior to injection. In the tumorigenesis assay, cells were inoculated subcutaneously into the posterior flank of athymic nude mice (five mice per group). The tumor formation was monitored daily. The latency was determined as the period of time required by tumors to reach a diameter of 10-15 mm. The mice that did not form tumors were observed for additional 8 weeks. For the lung colonization assay, cells were injected intravenously into the tail vein of athymic nude mice. Mice were killed 12 weeks postinjection. Tumors from skin or lungs were excised, fixed with formalin, embedded in paraffin, and sectioned in 5 mm. The sections were stained with hematoxylin/eosin and evaluated by light microscope for histological examination.
